BEHOLD: THE ENCYCLOPEDIA OF WORLD PROBLEMS & HUMAN POTENTIAL • Risk of Eco-Accidents

“The Great Work” = Enabled by Climate Emergency

Source: http://encyclopedia.uia.org/en/problem/132519

Risk of Eco-Accidents:

NATURE: Abrupt and widespread discontinuities exist in the fossil record of fauna and are considered evidence of widespread mass extinction of species. These low frequency events have been attributed to fluctuations in sea level, reversals of the geomagnetic fields (exposing the earth’s surface to lethal radiation), impacts of the earth by very large meteors (putting tons of dust into the atmosphere cutting off photosynthesis) and supernovae (causing catastrophic but temporary climate changes). There are also a range of potential man-made ecocatastrophes, such as triggering an earthquake with a an underground nuclear explosion. In addition, there are other more fantastic possibilities. The sun will expand into a red star engulfing Mercury and Venus and melting lead on the Earth. The moon can fall to earth, a comet, a swarm of meteorites or a black hole could collide with the earth. The earth will eventually loose its atmosphere. A life form might evolve destroying all of humankind.

This is the source material for the United Nations Agenda 2030 – the 17 Sustainable Development Goals. The carrying out of the implementation of the 17 Sustainable Development Goals is the partnership formed between the United Nations and the World Economic Forum known as “The Great Reset”…

See where this Masonic aptitude takes us…

DARPA Awards Moderna Therapeutics a Grant for up to $25 Million to Develop Messenger RNA Therapeutics™ • Moderna Press Release October 2013

Nothing suspicious about this here, word for word, directly from Moderna website:

Source: https://investors.modernatx.com/news-releases/news-release-details/darpa-awards-moderna-therapeutics-grant-25-million-develop

DARPA Awards Moderna Therapeutics a Grant for up to $25 Million to Develop Messenger RNA Therapeutics™

Research to focus on antibody production for immune defense

Cambridge, Mass., October 2, 2013—Moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.

Messenger RNA therapeutics™ can be designed to tap directly into the body’s natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, Moderna’s messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies.

“We are honored to be chosen by DARPA for this important grant, which will greatly accelerate our efforts to develop antibody messenger RNA therapeutics™ to combat a wide range of infectious diseases,” said Stéphane Bancel, president and founding CEO of Moderna. “We were awarded this major grant after an intense and rigorous scientific review, and it is a testament to our team’s progress and to the profound implications of messenger RNA therapeutics™ that our work was funded. We look forward to further expanding the development of our platform into this critically important new therapeutic area.”

This $24.6 million grant could support research for up to 5 years to advance promising antibody- producing drug candidates into preclinical testing and human clinical trials. The company also received a $0.7 million “seedling” grant from DARPA in March to begin work on the project.

This grant is part of a DARPA program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown. For more information about DARPA, visit http://www.darpa.mil/about-us/about-darpa.